C12 NBD Globotriaosylceramide
C12 NBD galactosylceramide is a biologically active derivative of galactosylceramide that is tagged with a fluorescent C12 nitrobenzoxadiazole (C12 NBD) group. C12 NBD galactosylceramide has been used to detect ceramide trihexoside.
For research use only. We do not sell to patients.
- CAS No.: 2692623-26-8
- Formula: C54H91N5O21
- Molecular Weight:1146.32
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
-
HY-W356117
C6 NBD Glucosylceramide
-
HY-D1577
C6 NBD Lactosylceramide
-
HY-141575
C12-NBD-ceramide
-
HY-141576
C6-NBD Sphinganine
-
HY-141577
C12-NBD Sphinganine
-
HY-D1575
C6 NBD Galactosylceramide
-
HY-147178
C-6 NBD-dihydro-Ceramide
-
HY-D1580
C12 NBD Lactosylceramide
-
HY-D1521
N-(NBD-Aminolauroyl)safingol
-
HY-145493
C12 NBD Galactosylceramide
Biological Activity
C12 NBD globotriaosylceramide accumulates in human umbilical vascular endothelial cells (HUVECs) treated with the α-galactosidase A inhibitor in a concentration-dependent manner[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
525
485
Chemical Information
-
CAS No. 2692623-26-8
-
Molecular Weight 1146.32
-
Formula C54H91N5O21
-
SMILES
O=C(CCCCCCCCCCCNC1=CC=C(C2=NON=C12)[N+]([O-])=O)N[C@@H](CO[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O[C@@]4(O[C@@H]([C@@H]([C@@H]([C@H]4O)O)O[C@@]5([C@@H]([C@H]([C@H]([C@H](O5)CO)O)O)O)[H])CO)[H])O)O)[C@@H](/C=C/CCCCCCCCCCCCC)O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Kassiani Kytidou, et al. Nicotiana benthamiana α-galactosidase A1.1 can functionally complement human α-galactosidase A deficiency associated with Fabry disease. J Biol Chem. 2018 Jun 29;293(26):10042-10058. [Content Brief]
[2]. Janet Hsu, et al. Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease. J Control Release. 2011 Feb 10;149(3):323-31. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
C12 NBD Globotriaosylceramide Related Classifications
HY-D1579 Related Classifications
Powered by Bioz